Asset profile
DS-7011a
Unknown / undisclosed
Evidence outlook · lead readout
NCT05638802 · Systemic Lupus Erythematosus
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05638802: The trial was randomized and double-blinded with a placebo arm, which are real methodological strengths, but the sample size was very small (19 drug vs 6 placebo) and unevenly split, and the pre-specified primary endpoint was safety (adverse event counts) rather than a disease-activity or clinical efficacy measure. Efficacy signals on skin and disease-activity scores were only secondary and descriptive, so this record does not demonstrate a statistically confirmed clinical benefit for DS-7011a.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.